



Y-axis: MFI (PE-signal)

Figure 1 a)



Y-axis: MFI (PE-signal)

Figure 1 b)




Figure 2




Figure 3





Figure 4



Y-axis: MFI (PE signal)

Figure 5




Figure 6





Figure 7



Y-axis: Signalling in %

Figure 8




Figure 9




CCRF-CEM
Median-PE
1500
1000
500
0
10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0} 10^{1}
IgG (nM)
306
406
503
KW0761
Anti-GFP
Anti-Human-PE
Hut78
Median-PE
1500
1000
500
0
10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0} 10^{1}
IgG (nM)
306
406
503
KW0761
Anti-GFP
Anti-Human-PE
L-428
Median-PE
600
400
200
0
10^{-2} 10^{-1} 10^{0} 10^{1} 10^{2}
IgG (nM)
306
406
503
KW0761
anti-GFP
anti-Human-PE

Figure 10

A


500
400
300
200
100
0
Median-PE
50% Human serum
10% Human serum
FACS buffer
KW0761
306
406
503
Streptavidin-PE
Unstained
Samples

B



150
100
50
0
Remaining Binding (%)
50% Human serum
10% Human serum
KW0761
306
406
503
strep-PE
Unstained
Samples

Figure 11



Alexa-647 (MDC-SNAP)
400
300
200
100
0
10 -3
10 -2
10 -1
10 0
10 1
10 2
IgG (nM)
306
406
503
KW0761
cells
Median-PE
150
100
50
0
10 -3
10 -2
10 -1
10 0
10 1
10 2
IgG (nM)
306
406
503
KW0761
cells

Figure 12



125%
100%
75%
50%
25%
0%
Luminescence (AU)
0
10-1
100
101
IgG (µg/ml)
No ligand
CCL17
CCL17+antibody
No ligand
CCL17
CCL17+antibody
25nM
125nM

Figure 13



150
100
50
0
-50
Cytotoxicity (%)
10 -6
10 -4
10 -2
10 0
10 2
IgG (nM)
306
406
503
KW0761
150
100
50
0
-50
Cytotoxicity (%)
10 -3
10 -2
10 -1
10 0
10 1
IgG (nM)
306
406
503
KW0761

Figure 14



150
100
50
0
Cytotoxicity (%)
306
406
503
KW0761
Max. Control (Triton)
Medium Control
306 (55%)
406 (56%)
503 (63 %)
KW0761 (75%)
Max. Control (Triton)
Medium Control

Figure 15



Body Weight
Body weight (g)
45
40
35
30
25
20
10 15 20 25 30 35 40 45 50 55
Days post TI
Gr. A (control)
Gr. B (KW0761)
Gr. C (306)
Gr. D (406)
Gr. E (503)
Relative Body Weight
% Starting weight
135
130
125
120
115
110
105
100
95
90
10 15 20 25 30 35 40 45 50 55
Days post TI
Gr. A (control)
Gr. B (KW0761)
Gr. C (306)
Gr. D (406)
Gr. E (503)

Figure 16



Group A (control)
Group B (KW0761)
Group C (306)
Group D (406)
Group E (503)
Tumor volume (mm3)
Days post TI
0
1000
2000
3000
4000
10 15 20 25 30 35 40 45 50 55

Figure 17



Animals alive >30 days
Tumor volume (mm3)
2000
1500
1000
500
0
10
20
30
40
50
Days post TI
3/10
4/10
1/5
4/10
Gr. A (control)
Gr. B (KW0761var)
Gr. C (306)
Gr. D (406)
Gr. E (503)
Survival proportions
Percent survival
100
80
60
40
20
0
10 15 20 25 30 35 40 45 50 55
Days post TI
Gr. A (control)
Gr. B (KW0761) ns
Gr. C (306) * P = 0.0117
Gr. D (406) ns
Gr. E (503) ** P = 0.0061
Tumor Doubling Time (Day23)
TDT (days)
15
10
5
0
*
Gr. A (Control)
Gr. B (KW0761)
Gr. C (306)
Gr. D (406)
Gr. E (503)

Figure 18




Figure 19